A selective antagonist of mineralocorticoid receptor eplerenone in cardiology practice

被引：0
|
作者：
Gegenava, B. B. [1 ]
Drapkina, O. M. [1 ]
机构：
[1] IM Sechenov First Moscow State Med Univ, Moscow 119991, Russia
来源：
RATIONAL PHARMACOTHERAPY IN CARDIOLOGY | 2015年 / 11卷 / 02期
关键词：
aldosterone; heart failure; atrial fibrillation; chronic renal failure; albuminuria; eplerenone; spironolactone; gynecomastia;
D O I：
10.20996/1819-6446-2015-11-2-177-181
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The role of aldosterone in pathophysiological processes is considered. The effects of the selective antagonist of mineralocorticoid receptor eplerenone are analyzed. The advantages of eplerenone compared with spironolactone are discussed.
引用
收藏
页码：177 / 181
页数：5
相关论文
共 50 条
  • [21] Absorption and Disposition of a Selective Aldosterone Receptor Antagonist, Eplerenone, in the Dog
    Chyung S Cook
    Liming Zhang
    JuDee S Fischer
    Pharmaceutical Research, 2000, 17 : 1426 - 1431
  • [22] Absorption and disposition of a selective aldosterone receptor antagonist, eplerenone, in the dog
    Cook, CS
    Zhang, LM
    Fischer, JS
    PHARMACEUTICAL RESEARCH, 2000, 17 (11) : 1426 - 1431
  • [23] Mineralocorticoid receptor antagonist eplerenone alleviates the reduction and dysfunction of endothelial progenitor cells in hypertensive patients
    Wang, Huanhuan
    Zhu, Aoshuang
    Wang, Xin
    Zang, Xuan
    Huang, Changgen
    Zhao, Jianzhong
    Ding, Zhijian
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 11 (08): : 7979 - 7986
  • [24] Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease
    Shah, Monarch
    Awad, Alaa S.
    Abdel-Rahman, Emaad M.
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (19)
  • [25] Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients
    Savoia, Carmine
    Touyz, Rhian M.
    Amiri, Farhad
    Schiffrin, Ernesto L.
    HYPERTENSION, 2008, 51 (02) : 432 - 439
  • [26] Mineralocorticoid receptor antagonists, a class beyond spironolactone - Focus on the special pharmacologic properties of eplerenone
    Seferovic, Petar M.
    Pelliccia, Francesco
    Zivkovic, Ivana
    Ristic, Arsen
    Lalic, Nebojsa
    Seferovic, Jelena
    Simeunovic, Dejan
    Milinkovic, Ivan
    Rosano, Giuseppe
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2015, 200 : 3 - 7
  • [27] Cardiovascular and Renal Outcomes with Finerenone, a Selective Mineralocorticoid Receptor Antagonist
    Srikanth Palanisamy
    Mario Funes Hernandez
    Tara I. Chang
    Kenneth W. Mahaffey
    Cardiology and Therapy, 2022, 11 : 337 - 354
  • [28] Use of mineralocorticoid receptor antagonist in ST elevation myocardial infarction
    Khan, Muhammad H.
    Gerson, Myron C.
    JOURNAL OF NUCLEAR CARDIOLOGY, 2022, 29 (05) : 2336 - 2339
  • [29] Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure:: effect on endothelial dysfunction
    Schäfer, A
    Fraccarollo, D
    Hildemann, SK
    Tas, P
    Ertl, G
    Bauersachs, J
    CARDIOVASCULAR RESEARCH, 2003, 58 (03) : 655 - 662
  • [30] The role of free radical oxidation in the kidneys in the nephroprotective action of eplerenone, a mineralocorticoid receptor antagonist, in experimental diabetes mellitus
    Zharikov, A. Yu
    Filinova, S. O.
    Mazko, O. N.
    Makarova, O. G.
    Bobrov, I. P.
    Bryukhanov, V. M.
    BYULLETEN SIBIRSKOY MEDITSINY, 2021, 20 (02): : 29 - 35
12345